Cureus

Interventional Mental Health: A Transdisciplinary Approach to Novel Psychiatric Care Delivery

Jonathann Kuo [1] , Tabitha Block [2] , Megan Nicklay [3] , Brandon Lau [4] , Marcel Green [4]

1. Regenerative and Anti-Aging Medicine, Hudson Health, New York, USA 2. Research, Hudson Health, New York, USA 3. Pain Management, Hudson Health, New York, USA 4. Psychiatry, Hudson Health, New York, USA

Corresponding author: Tabitha Block, tblock@hudson.health

Abstract

Mental health disorders are among the most common health conditions in the United States. Traditional clinical treatments rely on psychiatric counseling and, in many cases, prescription medications. We propose an innovative model, Interventional Mental Health, which employs a combination of modalities through a multifaceted approach to treat conditions that have exhibited limited responsiveness to traditional methods and individuals afflicted with multiple comorbidities simultaneously. We hypothesize that creating a unique treatment algorithm combining current therapeutic modalities such as Stellate Ganglion Blocks (SGB), Transcranial Magnetic Stimulation (TMS) therapy, and ketamine therapy, within a consolidated timeframe, will yield synergistic outcomes among patients presenting with comorbid post-traumatic stress disorder (PTSD), depression, and/or anxiety.

Introduction And Background

Interventional Mental Health (IMH) is a novel, multidisciplinary approach to the delivery of mental health services to psychiatric populations. Psychiatry is a discipline characterized by its specialized training, emphasizing psychopharmacology and psychotherapy domains [1]. These conventional interventions require little in the way of infrastructure or technology, and the technical and organizational requirements have more in common with the "Freudian Couch'' than the modern operating room. However, with the rapid pace of complex interventional care increasing, we present an overview of the opportunities and challenges for transdisciplinary care in psychiatric conditions and co-occurring presentations.

Sleep medicine is a medical subspecialty that includes doctors with prior training in pulmonary critical care, psychiatry, and neurology. The model we present for IMH is similar. Our model is based on a novel service design bringing together psychiatry and anesthesia. An interventional approach to psychiatric disorders requires knowledge and technical skills from psychiatry, pain management, anesthesiology, and even neurosurgery to deploy innovative and logistically intricate management strategies for mental health disorders. Common factors unite the systems and training needs for new treatments for post-traumatic stress disorder (PTSD), major depressive disorder (MDD), obsessive-compulsive disorder (OCD), generalized anxiety disorder (GAD), and more.

This review presents the integrated model for deploying three treatments initially: Stellate Ganglion Blocks (SGB) for PTSD and GAD, intravenous ketamine therapy for MDD, and Transcranial Magnetic Stimulation (TMS) for MDD and OCD. As GAD and PTSD are among the most common comorbid mental health conditions and have an estimated comorbidity rate of 50% in civilian populations and up to 90% in veteran populations, and approximately 50% of patients with PTSD also suffer from MDD, we present the evidence supporting the efficacy of these treatment modalities and discuss the rationale for combining what we consider prototypical interventions with the novel combination of several psychedelic treatments to improve clinical outcomes in myriad psychiatric disorders [2-4]. Further, our research site, which offers an Interventional Pain Fellowship, has begun the work of providing an integrated training experience for psychiatric conditions. Further, our research site, which offers an Interventional Pain Fellowship, has begun the work of providing an integrated training experience for psychiatric conditions. We propose an IMH Fellowship to establish a transdisciplinary training framework for the next generation of subspecialists.

Review

Conditions with new treatments opportunities

Generalized Anxiety Disorder (GAD)

GAD is among the most common psychiatric conditions, with a preponderance of symptoms suggesting the strong role of the brain-body connection in its pathophysiology [5]. GAD presents with characteristic psychological symptoms such as excessive, persistent, unrealistic fear, worry, and feeling overwhelmed [5-7]. These "thought and feeling" psychiatric symptoms present with somatic symptoms: non-specific physiological symptoms are diagnostic criteria (increased heart rate, shortness of breath, chest pain, hyperventilation, sweating, nausea, trembling). Moreover, cognitive symptoms (fear of losing control, fear of physical injury, confusion) and behavioral symptoms (restlessness, acing) are pathological in the absence of identifiable causes ("idiopathic") and they manifest as physiological responses in individuals responding to fear or stress [5-7].

Many known factors may increase the risk of developing GAD including stress, genetic factors, environmental factors, substance abuse, and physical or mental comorbidities (i.e. diabetes, depression, PTSD) [7]. Recent research also describes dysfunctional sympathetic nervous system signaling as a potential contributing factor in the development of GAD symptoms [8-10]. Cohort study data indicate augmented sympathetic nerve activity in response to chronic stress in anxiety sufferers compared to healthy individuals [8]. By using microneurography, brachial artery conductance, cardiorespiratory measures, and ambulatory 24-hr blood pressure to measure sympathetic nerve activity in both study groups, the results of this study indicate enhanced sympathetic nerve activity in individuals with chronic anxiety may be a modifiable risk or even causal factor in GAD [8].

Major Depressive Disorder (MDD) and Treatment Resistant Depression (TRD)

MDD is a psychiatric disease characterized by depressive symptoms, such as depressed mood, diminished interests, and impaired cognitive function. As at least 17 million US adults struggle with depression; understanding the pathophysiology of this disease is of utmost importance to the discovery of novel treatment options for this patient population [11]. In addition to a high prevalence rate, the presence of MDD is associated with an increased risk of developing other psychiatric disorders, such as GAD and PTSD [12-13]. Results from a prospective longitudinal cohort study over a 32-year duration exemplify the high comorbidity rates between GAD and MDD; of the 1037 individuals in the study cohort, 12% had comorbid GAD and MDD, but 72% of lifetime anxiety cases had a history of depression and 48% of lifetime depression cases had anxiety [12]. In addition, treatment-resistant depression (TRD), a subset of MDD, affects approximately 10%-30% of MDD patients, and individuals with TRD respond partially or not at all to traditional first-line antidepressant treatments, making this disease particularly difficult to treat [14].

As both the structural connections between neurons and between brain regions are formed and fine-tuned by the activity of neurotransmitters at neuronal synapses, alterations in neurotransmitter concentrations are widely accepted to play a role in the development and/or maintenance of depressive symptoms [12,15]. The focus of neurotransmitter-centric research has shifted from monoamines to glutamate [6-17], which has since been hypothesized to play a significant role in depression pathology [18-19]. Specifically, excessive glutamate signaling at N-methyl-D-aspartate receptors (NMDAR) may, at least in part, contribute to depression pathogenesis, and data have suggested that NMDAR dysfunction is associated with depression symptoms [18-19]. Another emerging model of depression pathophysiology extends beyond the role of neurotransmitters and focuses on functional connectivity and "circuit" disorders [20]. Additionally, brain-derived neurotrophic factor (BDNF), a "master-regulator" molecule with key roles in promoting neuroplasticity, expression is significantly reduced in patients with depression [21-24]. Further, animal models have revealed that depression-like behavior is associated with reduced BDNF expression in certain murine brain areas [21].

Given that traditional antidepressant treatments fail to provide relief for at least a subset of MDD patients (e.g. TRD populations) and the high comorbidity rates of MDD with other psychiatric disorders, designing therapeutic protocols for MDD has proven to be extremely complex due to the multifaceted nature of this condition (2-4,11). Despite this, in recent years MDD treatments have expanded significantly due to a greater understanding of its pathophysiology. With the approval of esketamine for TRD, and several different Transcranial Magnetic Stimulation (TMS) protocols (including the U.S. Food and Drug Administration breakthrough status for Stanford Neuromodulation Treatment), the array of potent and rapid-acting interventions with FDA approval is growing well beyond traditional "on the couch" psychiatric practice [25-26].

Post-traumatic Stress Disorder (PTSD)

PTSD is a debilitating psychiatric disorder that results from exposure to either real or perceived physical or mental injury/threat. PTSD is characterized by re-experience and avoidance symptoms such as intrusive thoughts, nightmares, flashbacks, dissociation, intense negative emotions, problems with sleep and concentration, irritability, increased reactivity, increased startle response, and hypervigilance [13]. As PTSD is one of the strongest correlates of suicidal ideation, lifetime suicide plans, and suicide attempts, PTSD has profound implications at the individual level and the global health level [27-28]. Individuals with PTSD are approximately 1.5 to 3 times more likely to experience co-occurring physical health conditions, such as diseases of bones and joints and neurological, respiratory, and cardiovascular illnesses [29]. Further, PTSD

and GAD have at least an estimated 50% comorbidity rate in civilian populations and up to 91% comorbidity rate in veteran populations [30]. PTSD can significantly impair individual, social, and family functioning, and high rates of PTSD comorbidity with depression, GAD, substance abuse disorders, and physical health problems ultimately result in poor individual-level outcomes [13].

Despite many known risk factors for developing PTSD, the exact molecular mechanisms leading to PTSD pathogenesis are not completely understood. Research indicates that traumatic exposures lead to chronic and dysfunctional activation of the stress response pathways of the hypothalamic-pituitary-adrenal (HPA) axis and the sympathetic nervous system (SNS) [31]. HPA and SNS stress responses are orchestrated by neuroendocrine signaling between the autonomic nervous system (ANS) and target organs in the periphery [32]. The SNS and parasympathetic nervous system (PNS), the two branches of the ANS, are responsible for producing antagonistic physiological effects. Both the SNS and the PNS coordinate with the central nervous system through associated nerve ganglia, which act as a junction between the central nervous system and the sympathetic or parasympathetic nerve fibers innervating target organs in the periphery. In healthy, normally functioning individuals, SNS responses to stimuli are generally appropriate in magnitude and duration. In addition to internal or external physical stressors, mental or emotional stress has also been shown to stimulate the sympathetic nervous system and elicit similar physiological responses to physical stress [31-35]. Overstimulation of the SNS can lead to inappropriate physiological responses, and, unfortunately, physiological manifestations of sympathetic stimulation do not exclusively occur as a response to appropriate stimuli for individuals with PTSD [32,36]. Research has evidenced that patients with PTSD exhibit overactive sympathetic reactivity and activity both during mental stress and under resting conditions [27-28]. Overactivation of the SNS results in an abnormal release of glucocorticoids and catecholamines and elevated levels of glucocorticoids have been widely accepted to have downstream effects on negative feedback inhibition of the HPA axis [31]. As such, the abnormal release of glucocorticoids following exposure to traumatic events can lead to changes in neuroendocrine functioning (via increased glucocorticoid binding to glucocorticoid receptors) which maintains a hyperactive sympathetic state [31]. Multiple peer-reviewed publications have suggested that recurrent trauma-related symptoms experienced by PTSD patients (i.e. hyperarousal, heightened physiological responses to stressors, and increased startle responses) may arise from enhanced, prolonged, and/or inappropriate activation of the SNS stress response [21-22,30,37-38].

Furthermore, the current PTSD diagnosis does not fully capture the severe psychological harm that occurs when people experience repeated or prolonged traumatic exposure. Complex PTSD has recently been identified as a distinct condition by the International Disease Classification (ICD-11). Complex PTSD symptoms can be similar but more prolonged and extreme than those of PTSD and the ICD-11 diagnosis characterizes Complex PTSD according to symptoms of affect dysregulation, negative self-concept, and disturbed relationships [39]. Some mental health professionals are beginning to distinguish between the two conditions and echoing the urgent demands for more research on treating this condition, despite the lack of guidance from the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) [40].

Metabolism and Psychiatric Disorders

While the presently available clinical data supports many hypotheses of the pathogenesis of mental disorders like PTSD, MDD, and GAD, it is important to note that emerging evidence highlights several shared common mechanistic bio-pathologies between metabolic dysfunction or abnormalities and such mental health disorders, including glucose hypo-metabolism, oxidative stress, inflammation, hormone abnormalities, and imbalances of neurotransmitter concentration or activity [41]. In recent years, research has revealed complex functions of molecules traditionally associated with metabolic disorders in the physiological systems that are involved in the development and/or maintenance of various psychiatric disorders. For example, in addition to its role in calcium and bone metabolism, Vitamin D is critical to numerous autocrine, paracrine, and endocrine processes which modulate the hypothalamic-pituitary-adrenal axis, a complex hormonal system that is implicated in several psychiatric disorders like PTSD, MDD, and GAD [42-43]. Further, as the vagus nerve, a major nerve of the parasympathetic nervous system, innervates the intestinal system and produces anxiolytic or anxiogenic signals in response to certain pathogenic bacteria in the gut microbiome, evidence suggests that the gut microbiome may influence brain function [44-45]. Numerous studies have demonstrated that patients with depression have distinct microbiota signatures when compared with healthy controls, highlighting a potential relationship between the gut microbiome and abnormal brain function [46]. Moreover, the effect of diet modification on symptom reduction of various psychiatric disorders has recently been studied to determine if dietary interventions with supposed psychopharmacologic properties could be used as potential treatments. Most notably, a 12-week randomized controlled trial investigating the effects of diet intervention on symptom severity in patients with depression reported significantly greater symptom improvement and significantly higher remission rates in the diet group relative to the control group [47].

Additionally, studies suggest that diet or lifestyle optimization and peptide therapy with anxiolytic peptides such as Selank, Semax, and PE 22-28 may serve as potential adjunct therapies for the treatment of several mental health disorders like PTSD, MDD, and GAD [47-51]. Although the evidence supporting a relationship between metabolic processes and the pathogenic mechanisms of various psychiatric disorders is biologically plausible, this field is relatively new and has thus been largely limited to evidence from animal studies and

observational studies.

Current therapeutics (SGB, TMS therapy, and ketamine therapy)

Stellate Ganglion Block (SGB) and Dual Sympathetic Blocks (DSB)

Recent neuroscience research has revealed Stellate Ganglion Blocks (SGB) to be a promising new therapeutic avenue for individuals with PTSD and trauma-related anxiety. SGB is a minimally invasive procedure in which local anesthetic is injected into and around the cervical stellate ganglion nerve clusters under ultrasound guidance. Clinical studies have evidenced that SGB may provide significant and long-lasting symptom relief for patients with PTSD and trauma-related anxiety [30,52-59]. When used in conjunction with trauma-focused psychotherapy, SGB has been shown to have a 70%-80% success rate in treating PTSD symptoms [52-59]. A clinical case study involving 166 active duty service members with multiple combat deployments with PTSD who elected to receive an SGB demonstrated a <70% success rate of SGB, as measured by a reduction of at least 10 points in the PTSD Checklist for DSM-5 (PCL-5) symptom scores [58]. This study also reported the clinical benefits produced by SGB persisted beyond three to six months post-procedure in >70% of study participants [58]. Furthermore, a recent randomized clinical trial investigating SGB outcomes in patients with PTSD demonstrated that those who received SGB reported significantly improved PTSD assessment scores compared with patients in the placebo groups, as measured by a two times greater reduction in Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) score [57]. This study also reported secondary outcome improvement in anxiety symptoms, as measured by a reduction in Generalized Anxiety Disorder 7-Item Scale (GAD-7) scores in PTSD patients [57].

These studies support the safety and efficacy of a standard right-sided, single-level (C6) SGB for the treatment of PTSD. In clinical practice, however, researchers noted some patients who did not respond to an SGB as anticipated, despite having similar clinical presentations to other patients that did respond well to the standard C6 SGB. To account for this discrepancy in clinical observation, a case study involving an analysis of 147 patients suggested treating two levels of the sympathetic chain to account for anatomic variations in the course of the cervical sympathetic chain and the location of the middle cervical ganglion [59]. This study treated 103 participants with a standard C6 SGB and 44 participants with a two-level SGB at C6 and C4 (herein referred to as Dual Sympathetic Blocks or DSB). The mean baseline PCL scores for each group were compared to one another and both groups experienced clinically significant improvement in PTSD symptoms (i.e. a PCL score reduction of at least 10 points). The (single-level) SGB group responded with a mean improvement in the PCL-5 score of 25.2 points, while the DSB group responded with a greater improvement of 31.78 points [59]. Based on this initial clinical report for the two-level cervical sympathetic chain block (DSB) treatment modality, a right-sided two-level cervical sympathetic chain block (DSB) administered at C6 and C4 levels appears to be safe and more effective than a standard SGB in the treatment of PTSD symptoms.

Normal anatomic variation along the course of the cervical sympathetic chain and in the location of the middle cervical ganglion reasonably supports the DSB approach. Furthermore, research suggests a left-sided SGB has different effects than a right-sided SGB. A large analysis [58] of blood pressure (BP) and heart rate (HR) changes after right and left SGBs indicated higher sympathetic dominance on the right while higher parasympathetic dominance on the left side. Additionally, a retrospective study [56] of 205 PTSD patients found 20 who did not respond to a right SGB and subsequently treated 10 of those patients with a left-sided SGB. This resulted in clinically significant improvement where 90% responded favorably to the left-sided SGB and the mean PCL-5 improvement was 28.5 points [56]. For these reasons, the preferred modality here is the DSB approach performed on both the right and left sides, as this approach has demonstrated consistent and superior clinical efficacy when compared to a single-level, single-sided block.

Ketamine Therapy

In recent years, overwhelming evidence has substantiated the potential benefits of ketamine in treating psychiatric disorders, particularly depression and chronic pain [50-51]. Ketamine can provide rapid and significant improvements in depressive symptoms, even for patients with treatment-resistant depression [50-51]. Ketamine is a drug classified as a dissociative anesthetic hallucinogen because it exerts its biochemical actions on the glutamatergic system. Tight regulation of extracellular glutamate levels is of utmost physiological importance because glutamate is found in extremely high concentrations and the excitatory effects of glutamate are very potent [52]. Glutamate acts on two classes of receptors, ionotropic glutamate receptors, including N-methyl-D-aspartate (NMDA), α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA), and kainate (KA), as well as metabotropic glutamate receptors [52]. In healthy brains, glutamate signaling through NMDARs contributes to neuroplasticity [18]. NMDAR dysfunction is associated with depression [18-19]. Data has also suggested that excessive glutamate signaling at NMDA receptors may, at least in part, contribute to depression pathogenesis [18,34]. Ketamine disrupts the glutamatergic system and blocks the activity of NMDA receptors on gamma-aminobutyric acid (GABA)ergic interneurons, leading to downstream increases in extracellular glutamate levels [52].

Reports from numerous clinical trials have demonstrated that a single intravenous ketamine infusion can produce a significantly rapid and sustained antidepressant response [53-54]. The mechanism by which

ketamine improves depressive symptoms is not completely understood, but, in addition to affecting NMDAR signaling, ketamine may affect AMPA receptors (AMPARs), a different class of ionotropic glutamate receptors. Glutamine action at AMPAR is responsible for modifying synaptic strength and supporting cellular remodeling in response to learning [55-56]. AMPA receptors and NMDA receptors are antagonists; activation of AMPAR results in the inhibition of further glutamate release and reduces glutamate activity [21-22]. Ketamine modulates glutamate activity in the brain in two ways: by blocking NMDA receptors and by activating AMPA receptors [21]. Ketamine has been shown to block NMDA ion channels [18,21]. Ketamine-mediated blockade of NMDA ion channels causes glutamate release from NMDAR into the extracellular space, effectively "freeing" glutamate to act at AMPA receptor sites [18,21]. The subsequent binding of glutamate to AMPAR may be partly responsible for the antidepressant effects of ketamine by inducing inhibition of glutamate recycling and release [21].

Additionally, ketamine may also elicit antidepressant effects by modulating the production of neurotrophic factors such as brain-derived neurotrophic factor (BDNF) [12-24,57-58]. BDNF expression has been shown to be significantly reduced in patients with depression, and several meta-analyses have revealed that patients with depression exhibit significantly reduced blood BDNF levels [21-23]. Animal models of stress have demonstrated that depression-like behavior is associated with reduced BDNF expression in certain murine brain areas [21]. It has been hypothesized that ketamine significantly increases BDNF expression through AMPAR-mediated activation of the mTOR pathway [24]. Evidence now supports that BDNF is required for and may partly mediate the significant and rapid antidepressant effects of ketamine [22-24,57-58].

As a powerful regulator of glutamate, ketamine has many clinical applications in expanding treatment options for mental health disorders like depression. In particular, the incredibly rapid onset of antidepressant effects that ketamine infusions produce is of utmost clinical importance to patients with depression suffering from suicidal ideation. A recent meta-analysis concluded that single-dose intravenous ketamine infusions remarkably reduce patients' suicidal thoughts as soon as two hours after infusion [58]. These results highlight ketamine as a fast-acting and successful therapeutic avenue for individuals struggling with severe depression. In addition, approximately 40% of patients with treatment-resistant depression (TRD) present with cognitive deficits [59]. The results from another recent systematic review suggest that TRD patients treated with ketamine infusions showed improved complex and simple working memory, improved processing speed, and improved verbal learning memory [59]. These results provide further evidence for the safety and efficacy of therapeutic ketamine in depression treatment protocols.

Transcranial Magnetic Stimulation (TMS) Therapy

Conventional treatments for MDD include psychological therapy methods and pharmacological antidepressant medications such as selective serotonin reuptake inhibitors, serotonin and noradrenaline reuptake inhibitors, tricyclic antidepressants, and electroconvulsive therapy [60]. Recent discoveries in depression treatment research have revealed TMS therapy as a novel therapeutic option with significantly fewer potential adverse effects. TMS therapy is a non-invasive treatment option with an excellent safety and efficacy profile that has been designed to provide significant and long-lasting symptom relief from numerous psychiatric disorders like depression, migraines, and obsessive-compulsive disorder [61-62].TMS is a noninvasive brain stimulation therapy that involves the application of targeted magnetic pulses to the superficial layers of the cerebral cortex. This magnetic field can locally induce small electrical currents that stimulate nerve cells in mood-controlling areas of the brain [11,61-64]. These small electrical currents are both powerful and precise enough to elicit an action potential in neurons in the frontal lobe, hippocampus, temporal lobe, thalamus, striatum, and amygdala, effectively resulting in increased release of neurotransmitters into the synapse [61-64]. In patients with depression, alterations in functional connectivity are prominent, and the use of functional connectivity for TMS targeting is part of the workflow for neuronavigated TMS, as described in the pivotal trial by Cole et al. for Stanford Neuromodulation Treatment [25]. TMS therapy addresses the neurotransmitter imbalance associated with depression by stimulating targeted neurotransmitter release in mood-controlling regions of the brain [61-62]. TMS therapy may restore neuronal circuit activity in patients with depression and has been shown to provide statistically and clinically significant improvement of depressive symptoms [61-67]. Symptom improvement in mood, reduced days of experiencing depressive symptoms and increased engagement in socializing have been reported as early as two weeks following the completion of the TMS therapy protocol [68]. Approximately 83% of patients treated with TMS therapy showed significant improvements in depressive symptoms, and 62% of patients reported symptom relief lasting through 12 months [66-67,69].

The IMH approach

Results from myriad clinical trials support the safety and efficacy of each of the three therapeutic avenues included in our proposed Interventional Mental Health subspecialty for the management of various psychiatric disorders. Extensive data from clinical studies evaluating Stellate Ganglion Blocks (SGB) suggest these procedures may provide clinically meaningful and long-lasting symptom relief for patients with PTSD and trauma-related anxiety. Intravenous ketamine therapy has been repeatedly shown to provide rapid, significant, and long-lasting improvements in depressive symptoms, even for patients with TRD. Further, TMS therapy has also been shown to provide a marked improvement in depressive symptoms in patients with MDD.

2023 Kuo et al. Cureus 15(8): e43533. DOI 10.7759/cureus.43533

5 of 10

Given that SGB, intravenous ketamine therapy and TMS therapy utilize distinct molecular and physiological pathways to achieve clinically meaningful symptom relief of PTSD, anxiety, and depression and the notably high comorbidity rates between these disorders, employing a combination of treatment modalities to treat multiple comorbidities simultaneously through an IMH approach may improve therapeutic effectiveness and efficiency. We hypothesize that creating unique treatment algorithms which combine these therapeutic approaches in a consolidated time frame will produce synergistic outcomes in at least a subset of patients with comorbid PTSD, depression, and/or anxiety. Implementing IMH-centered treatment protocols involving a combination of DSB and/or intravenous ketamine therapy and/or TMS therapy will provide valuable insight into understanding what combination of therapeutic modalities is the most efficacious for certain conditions.

Clinical trial data suggests two SGB treatments performed a maximum of two weeks apart are most effective in reducing PCL-5 scores and significantly improving PTSD symptoms [46]. The antidepressant effects of a single dose of intravenous ketamine persist for a maximum of seven days, so numerous studies have explored the safety and efficacy of repeated intravenous ketamine infusions over several study periods (e.g. three to six times a week for one to six weeks). Among these, one study evaluated the antidepressant effects of a series of six intravenous ketamine (0.5mg/kg) infusions in patients with TDR three times weekly over a 12-day study period and reported an overall response rate of 70.8% [70]. The authors also noted a significant reduction in Montgomery-Åsberg Depression Rating Scale (MADRS) scores two hours after the first ketamine infusion, which was also largely sustained throughout the study [70]. As such, presently available clinical data indicates a series of six intravenous ketamine sessions administered over two weeks is required for prolonged antidepressant effects. Likewise, five daily treatment sessions over three to six weeks (a total of 20 to 30 sessions) of TMS therapy are required for effective and prolonged clinical benefits for patients with MDD [71]. As evidence strongly supports the safety and efficacy of SGB, ketamine therapy, and TMS therapy as independent treatment modalities, one would reasonably anticipate that sequential administration of these therapies could provide synergistic and potentiated clinical benefits over a condensed time frame.

The IMH approach we propose begins by performing a unilateral DSB directly followed by intravenous ketamine therapy - all in the span of a single appointment. We will administer the ketamine infusion 40 minutes after the SGB is performed to minimize any interaction between ketamine and propofol, the anesthetic we use for sedation. We hypothesize that merging the time frame in which patients receive these treatments will potentiate the therapeutic benefits of each individual therapy. In our clinical practice, we have observed that some patients with moderate to severe anxiety can occasionally experience unpleasant intravenous ketamine therapy sessions due to the dissociative effects of ketamine. As such, we believe performing DSB before intravenous ketamine therapy may reduce excessive sympathetic signaling during ketamine therapy sessions because DSBs have been shown to alleviate symptoms of sympathetic reactivity and anxiety-related PTSD symptoms, which are frequently concomitant with depression. Additionally, research suggests that DSBs improve cerebral perfusion through vasodilation mechanisms, which may aid in the efficacy of ketamine therapy and TMS therapy (80). If performed consecutively over the duration of a one-week treatment intensive, we hypothesize that two DSBs followed by six intravenous ketamine sessions and the completion of the Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT) accelerated TMS therapy protocol may lead to better patient experiences and improved overall outcomes.

With regard to the suitability of the IMH approach for different age groups, in our clinical practice, we have successfully treated pediatric psychiatric patients as young as eight years old with SGB procedures under the multidisciplinary care team of a child and adolescent psychiatrist, anesthesiologist, and their treating therapist. In many of these younger patients with significant psychiatric issues, polypharmacy approaches have often been trialed with inadequate efficacy. Some of the modalities presented by the IMH approach (i.e. SGB and TMS therapy) may offer a novel, non-pharmacologic treatment approach for a subset of these patients. While there are several published case reports that describe safe and efficacious results of SGB in pediatric patients as young as 18 months old, supporting evidence from clinical trials is not yet available [72-74]. Further, the safety and efficacy of ketamine therapy in adolescent populations between the ages of 12 and 18 with depression have been demonstrated across numerous clinical studies, indicating that ketamine therapy may be appropriate not only for adults with depression but also for some adolescents with depression [75-76]. Additionally, TMS therapy has been demonstrated to be safe and effective in pediatric and adolescent psychiatric populations from 12-18 years old across various clinical studies [77-78]. Potential contraindications and side effects of SGB procedures (i.e. risk of infection, bleeding, nerve damage to the vagus nerve, recurrent nerve or brachial plexus roots, intolerability secondary to pain), intravenous ketamine therapy (i.e. psychomimetic effects that lead to long-term cognitive deficits, the potential for abuse and dependence) and TMS therapy (i.e. seizure) can be minimized in the proposed IMH approach because the multidisciplinary nature of this novel medical discipline calls for the collaboration of highly trained medical professionals in their respective fields who can contribute their specific skill sets appropriately.

Limitations

While the IMH approach may be successful in creating a targeted mental health treatment modality, it may be cost-ineffective, primarily due to the lack of readily available insurance coverage. Moreover, the need for a

definitive certainty regarding how to precisely structure a combined intervention treatment protocol still remains. Additionally, the scarcity of medical professionals equipped with the requisite training and suitable practices to support this approach contributes to its limitations. As such, these factors collectively underscore the need for specialized expertise to inform practice standards for treatment protocols as well as the cost-effectiveness of the IMH approach relative to other treatment modalities. Additionally, though we hypothesize that the combination of treatments in the IMH approach is potentially synergistic in mechanisms of action to yield additive clinical efficacy, randomized controlled trials are needed to conclusively determine whether that additive effect is actual.

Strengths and implications

This paper proposes the utility of combing interventional mental health treatments to improve treatment efficacy for select psychiatric conditions, particularly in treatment-resistant patient populations, as well as adding clinically indicated combinations to practice standard treatment protocols. The implications of this research are significant, expanding the range of interventions for treatment-resistant populations, and also offering an opportunity for swifter symptom improvement to subsequently improve engagement with and efficacy of conventional treatment modalities.

Conclusions

The implications of this research could be significant, as it offers a promising alternative for individuals whose conditions have been challenging to address using conventional treatments alone. If proven effective, this IMH model could expand treatment options, offering hope to patients who previously had limited therapeutic avenues. Furthermore, our emphasis on utilizing a consolidated timeframe for administering different therapeutic modalities could lead to more efficient treatment, reducing the overall duration of interventions and potentially minimizing the burden on both patients and healthcare resources.

Overall, the IMH focus on combining diverse therapeutic approaches to address complex mental health conditions showcases a forward-thinking and novel approach to mental healthcare. By exploring new avenues and testing the synergistic potential of different interventions, this research contributes to the ongoing efforts to improve mental health treatment and, ultimately, the well-being of affected individuals.

Additional Information

Disclosures

Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: **Payment/services info:** All authors have declared that no financial support was received from any organization for the submitted work. **Financial relationships:** All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. **Other relationships:** All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

1. Accreditation council for graduate medical education (ACGME) program requirements for graduate medical education in psychiatry. (2023). Accessed: May 20, 2023: https://www.acgme.org/globalassets/pfassets/programrequirements/400_psychiatry_2023.pdf.
2. Knowles KA, Sripada RK, Defever M, Rauch SA: Comorbid mood and anxiety disorders and severity of posttraumatic stress disorder symptoms in treatment-seeking veterans. Psychol Trauma. 2019, 11:451-8. 10.1037/tra0000383
3. Price M, Legrand AC, Brier ZM, Hébert-Dufresne L: The symptoms at the center: examining the comorbidity of posttraumatic stress disorder, generalized anxiety disorder, and depression with network analysis. J Psychiatr Res. 2019, 109:52-8. 10.1016/j.jpsychires.2018.11.016
4. Flory JD, Yehuda R: Comorbidity between post-traumatic stress disorder and major depressive disorder: alternative explanations and treatment considerations. Dialogues Clin Neurosci. 2015, 17:141-50. 10.31887/DCNS.2015.17.2/jflory
5. DeMartini J, Patel G, Fancher TL: Generalized anxiety disorder. Ann Intern Med. 2019, 170:ITC49-64. 10.7326/AITC201904020
6. Munir S, Takov V: Generalized anxiety disorder. StatPearls Publishing, Treasure Island (FL); 2022.
7. Holwerda SW, Luehrs RE, Gremaud AL, et al.: Relative burst amplitude of muscle sympathetic nerve activity is an indicator of altered sympathetic outflow in chronic anxiety. J Neurophysiol. 2018, 120:11-22. 10.1152/jn.00064.2018
8. Wenner MM: Sympathetic activation in chronic anxiety: not just at the "height" of stress. Editorial Focus on "Relative burst amplitude of muscle sympathetic nerve activity is an indicator of altered sympathetic outflow in chronic anxiety". J Neurophysiol. 2018, 120:7-8. 10.1152/jn.00220.2018
9. Teed AR, Feinstein JS, Puhl M, et al.: Association of generalized anxiety disorder with autonomic hypersensitivity and blunted ventromedial prefrontal cortex activity during peripheral adrenergic stimulation: a randomized clinical trial. JAMA Psychiatry. 2022, 79:323-32. 10.1001/jamapsychiatry.2021.4225
10. McCarter T: Depression overview. Am Health Drug Benefits. 2008, 1:44-51.
11. Brigitta B: Pathophysiology of depression and mechanisms of treatment . Dialogues Clin Neurosci. 2002,

4:7-20. 10.31887/DCNS.2002.4.1/bbondy

12. Moffitt TE, Harrington H, Caspi A, Kim-Cohen J, Goldberg D, Gregory AM, Poulton R: Depression and generalized anxiety disorder: cumulative and sequential comorbidity in a birth cohort followed prospectively to age 32 years. Arch Gen Psychiatry. 2007, 64:651-60. 10.1001/archpsyc.64.6.651

13. Miao XR, Chen QB, Wei K, Tao KM, Lu ZJ: Posttraumatic stress disorder: from diagnosis to prevention . Mil Med Res. 2018, 5:32. 10.1186/s40779-018-0179-0

14. Al-Harbi KS: Treatment-resistant depression: therapeutic trends, challenges, and future directions. Patient Prefer Adherence. 2012, 6:369-88. 10.2147/PPA.S29716

15. Zhang FF, Peng W, Sweeney JA, Jia ZY, Gong QY: Brain structure alterations in depression: psychoradiological evidence. CNS Neurosci Ther. 2018, 24:994-1003. 10.1111/cns.12835

16. Zorumski CF, Izumi Y, Mennerick S: Ketamine: NMDA receptors and beyond . J Neurosci. 2016, 36:11158-64. 10.1523/JNEUROSCI.1547-16.2016

17. Siu A, Drachtman R: Dextromethorphan: a review of N-methyl-d-aspartate receptor antagonist in the management of pain. CNS Drug Rev. 2007, 13:96-106. 10.1111/j.1527-3458.2007.00006.x

18. Adell A: Brain NMDA receptors in schizophrenia and depression . Biomolecules. 2020, 10:10.3390/biom10060947

19. Abdallah CG, De Feyter HM, Averill LA, et al.: The effects of ketamine on prefrontal glutamate neurotransmission in healthy and depressed subjects. Neuropsychopharmacology. 2018, 43:2154-60. 10.1038/s41386-018-0136-3

20. Siddiqi SH, Taylor SF, Cooke D, Pascual-Leone A, George MS, Fox MD: Distinct symptom-specific treatment targets for circuit-based neuromodulation. Am J Psychiatry. 2020, 177:435-46. 10.1176/appi.ajp.2019.19090915

21. Lazarevic V, Yang Y, Flais I, Svenningsson P: Ketamine decreases neuronally released glutamate via retrograde stimulation of presynaptic adenosine A1 receptors. Mol Psychiatry. 2021, 26:7425-35. 10.1038/s41380-021-01246-3

22. Sen S, Duman R, Sanacora G: Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications. Biol Psychiatry. 2008, 64:527-32. 10.1016/j.biopsych.2008.05.005

23. Guilloux JP, Douillard-Guilloux G, Kota R, et al.: Molecular evidence for BDNF- and GABA-related dysfunctions in the amygdala of female subjects with major depression. Mol Psychiatry. 2012, 17:1130-42. 10.1038/mp.2011.113

24. Yang T, Nie Z, Shu H, et al.: The role of BDNF on neural plasticity in depression . Front Cell Neurosci. 2020, 14:82. 10.3389/fncel.2020.00082

25. Cole EJ, Phillips AL, Bentzley BS, et al.: Stanford neuromodulation therapy (SNT): a double-blind randomized controlled trial. Am J Psychiatry. 2022, 179:132-41. 10.1176/appi.ajp.2021.20101429

26. Swainson J, Thomas RK, Archer S, et al.: Esketamine for treatment resistant depression . Expert Rev Neurother. 2019, 19:899-911. 10.1080/14737175.2019.1640604

27. Nichter B, Stein MB, Norman SB, Hill ML, Straus E, Haller M, Pietrzak RH: Prevalence, correlates, and treatment of suicidal behavior in US military veterans: results from the 2019-2020 National Health and Resilience in Veterans Study. J Clin Psychiatry. 2021, 82:10.4088/JCP.20m13714

28. Holliday R, Borges LM, Stearns-Yoder KA, Hoffberg AS, Brenner LA, Monteith LL: Posttraumatic stress disorder, suicidal ideation, and suicidal self-directed violence among U.S. military personnel and veterans: a systematic review of the literature from 2010 to 2018. Front Psychol. 2020, 11:1998. 10.3389/fpsyg.2020.01998

29. Husarewycz MN, El-Gabalawy R, Logsetty S, Sareen J: The association between number and type of traumatic life experiences and physical conditions in a nationally representative sample. Gen Hosp Psychiatry. 2014, 36:26-32. 10.1016/j.genhosppsych.2013.06.003

30. Forneris CA, Gartlehner G, Brownley KA, et al.: Interventions to prevent post-traumatic stress disorder: a systematic review. Am J Prev Med. 2013, 44:635-50. 10.1016/j.amepre.2013.02.013

31. Bryant RA: Post-traumatic stress disorder: a state-of-the-art review of evidence and challenges . World Psychiatry. 2019, 18:259-69. 10.1002/wps.20656

32. Goldstein B: Anatomy of the peripheral nervous system . Phys Med Rehabil Clin N Am. 2001, 12:207-36. 10.1016/s1047-9651(18)30066-4

33. De Gregorio D, Aguilar-Valles A, Preller KH, Heifets BD, Hibicke M, Mitchell J, Gobbi G: Hallucinogens in mental health: preclinical and clinical studies on LSD, psilocybin, MDMA, and ketamine. J Neurosci. 2021, 41:891-900. 10.1523/JNEUROSCI.1659-20.2020

34. Chaudhry A, Kamali A, Herzka DA, Wang KC, Carrino JA, Blitz AM: Detection of the stellate and thoracic sympathetic chain ganglia with high-resolution 3D-CISS MR imaging. AJNR Am J Neuroradiol. 2018, 39:1550-4. 10.3174/ajnr.A5698

35. Kwon OJ, Pendekanti S, Fox JN, et al.: Morphological spectra of adult human stellate ganglia: implications for thoracic sympathetic denervation. Anat Rec (Hoboken). 2018, 301:1244-50. 10.1002/ar.23797

36. Marsden WN: Stressor-induced NMDAR dysfunction as a unifying hypothesis for the aetiology, pathogenesis and comorbidity of clinical depression. Med Hypotheses. 2011, 77:508-28. 10.1016/j.mehy.2011.06.021

37. Lebois LA, Wolff JD, Ressler KJ: Neuroimaging genetic approaches to posttraumatic stress disorder . Exp Neurol. 2016, 284:141-52. 10.1016/j.expneurol.2016.04.019

38. Lynch JH: Stellate ganglion block treats posttraumatic stress: an example of precision mental health . Brain Behav. 2020, 10:e01807. 10.1002/brb3.1807

39. Maercker A: Development of the new CPTSD diagnosis for ICD-11 . Borderline Personal Disord Emot Dysregul. 2021, 8:7. 10.1186/s40479-021-00148-8

40. Karatzias T, Cloitre M: Treating adults with complex posttraumatic stress disorder using a modular approach to treatment: rationale, evidence, and directions for future research. J Trauma Stress. 2019, 32:870-6. 10.1002/jts.22457

41. Lynch JH, Mulvaney SW, Kim EH, de Leeuw JB, Schroeder MJ, Kane SF: Effect of stellate ganglion block on

2023 Kuo et al. Cureus 15(8): e43533. DOI 10.7759/cureus.43533

8 of 10

specific symptom clusters for treatment of post-traumatic stress disorder. Mil Med. 2016, 181:1135-41. 10.7205/MILMED-D-15-00518

42. Lipov EG, Joshi JR, Sanders S, Slavin KV: A unifying theory linking the prolonged efficacy of the stellate ganglion block for the treatment of chronic regional pain syndrome (CRPS), hot flashes, and posttraumatic stress disorder (PTSD). Med Hypotheses. 2009, 72:657-61. 10.1016/j.mehy.2009.01.009

43. Lipov EG, Navaie M, Brown PR, Hickey AH, Stedje-Larsen ET, McLay RN: Stellate ganglion block improves refractory post-traumatic stress disorder and associated memory dysfunction: a case report and systematic literature review. Mil Med. 2013, 178:e260-4. 10.7205/MILMED-D-12-00290

44. Lynch JH, Muench PD, Okiishi JC, Means GE, Mulvaney SW: Behavioral health clinicians endorse stellate ganglion block as a valuable intervention in the treatment of trauma-related disorders. J Investig Med. 2021, 69:989-93. 10.1136/jim-2020-001693

45. Mulvaney SW, Lynch JH, Curtis KE, Ibrahim TS: The successful use of left-sided stellate ganglion block in patients that fail to respond to right-sided stellate ganglion block for the treatment of post-traumatic stress disorder symptoms: a retrospective analysis of 205 patients. Mil Med. 2022, 187:e826-9. 10.1093/milmed/usab056

46. Rae Olmsted KL, Bartoszek M, Mulvaney S, et al.: Effect of stellate ganglion block treatment on posttraumatic stress disorder symptoms: a randomized clinical trial. JAMA Psychiatry. 2020, 77:130-8. 10.1001/jamapsychiatry.2019.3474

47. Mulvaney SW, Lynch JH, Hickey MJ, Rahman-Rawlins T, Schroeder M, Kane S, Lipov E: Stellate ganglion block used to treat symptoms associated with combat-related post-traumatic stress disorder: a case series of 166 patients. Mil Med. 2014, 179:1133-40. 10.7205/MILMED-D-14-00151

48. Mulvaney SW, Curtis KE, Ibrahim TS: Comparison C6 stellate ganglion versus C6 and C4 cervical sympathetic chain blocks for treatment of posttraumatic stress disorder (PTSD): analysis of 147 patients. J Neurol Disord Stroke. 2020, 7:1163. 10.47739/2334-2307/1163

49. Yokota S, Taneyama C, Goto H: Different effects of right and left stellate ganglion block on systolic blood pressure and heart rate. Open J Anesthesiol. 2013, 3:143-7. 10.4236/ojanes.2013.33033

50. Mandal S, Sinha VK, Goyal N: Efficacy of ketamine therapy in the treatment of depression . Indian J Psychiatry. 2019, 61:480-5. 10.4103/psychiatry.IndianJPsychiatry_484_18

51. Marcantoni WS, Akoumba BS, Wassef M, Mayrand J, Lai H, Richard-Devantoy S, Beauchamp S: A systematic review and meta-analysis of the efficacy of intravenous ketamine infusion for treatment resistant depression: January 2009 - January 2019. J Affect Disord. 2020, 277:831-41. 10.1016/j.jad.2020.09.007

52. Niciu MJ, Kelmendi B, Sanacora G: Overview of glutamatergic neurotransmission in the nervous system . Pharmacol Biochem Behav. 2012, 100:656-64. 10.1016/j.pbb.2011.08.008

53. Phillips JL, Norris S, Talbot J, et al.: Single, repeated, and maintenance ketamine infusions for treatment-resistant depression: a randomized controlled trial. Am J Psychiatry. 2019, 176:401-9. 10.1176/appi.ajp.2018.18070834

54. Singh JB, Fedgchin M, Daly EJ, et al.: A double-blind, randomized, placebo-controlled, dose-frequency study of intravenous ketamine in patients with treatment-resistant depression. Am J Psychiatry. 2016, 173:816-26. 10.1176/appi.ajp.2016.16010037

55. Chater TE, Goda Y: The role of AMPA receptors in postsynaptic mechanisms of synaptic plasticity . Front Cell Neurosci. 2014, 8:401. 10.3389/fncel.2014.00401

56. Marchi M, Raiteri L, Risso F, et al.: Effects of adenosine A1 and A2A receptor activation on the evoked release of glutamate from rat cerebrocortical synaptosomes. Br J Pharmacol. 2002, 136:434-40. 10.1038/sj.bjp.0704712

57. Fukumoto K, Fogaça MV, Liu RJ, Duman C, Kato T, Li XY, Duman RS: Activity-dependent brain-derived neurotrophic factor signaling is required for the antidepressant actions of (2R,6R)-hydroxynorketamine. Proc Natl Acad Sci U S A. 2019, 116:297-302. 10.1073/pnas.1814709116

58. Xiong J, Lipsitz O, Chen-Li D, et al.: The acute antisuicidal effects of single-dose intravenous ketamine and intranasal esketamine in individuals with major depression and bipolar disorders: a systematic review and meta-analysis. J Psychiatr Res. 2021, 134:57-68. 10.1016/j.jpsychires.2020.12.038

59. Gill H, Gill B, Rodrigues NB, et al.: The effects of ketamine on cognition in treatment-resistant depression: a systematic review and priority avenues for future research. Neurosci Biobehav Rev. 2021, 120:78-85. 10.1016/j.neubiorev.2020.11.020

60. Duval F, Lebowitz BD, Macher JP: Treatments in depression . Dialogues Clin Neurosci. 2006, 8:191-206. 10.31887/DCNS.2006.8.2/fduval

61. Chail A, Saini RK, Bhat PS, Srivastava K, Chauhan V: Transcranial magnetic stimulation: a review of its evolution and current applications. Ind Psychiatry J. 2018, 27:172-80. 10.4103/ipj.ipj_88_18

62. Stultz DJ, Osburn S, Burns T, Pawlowska-Wajswol S, Walton R: Transcranial magnetic stimulation (TMS) safety with respect to seizures: a literature review. Neuropsychiatr Dis Treat. 2020, 16:2989-3000. 10.2147/NDT.S276635

63. Post A, Keck ME: Transcranial magnetic stimulation as a therapeutic tool in psychiatry: what do we know about the neurobiological mechanisms?. J Psychiatr Res. 2001, 35:193-215. 10.1016/s0022-3956(01)00023-1

64. Carpenter LL, Janicak PG, Aaronson ST, et al.: Transcranial magnetic stimulation (TMS) for major depression: a multisite, naturalistic, observational study of acute treatment outcomes in clinical practice. Depress Anxiety. 2012, 29:587-96. 10.1002/da.21969

65. Avery DH, Isenberg KE, Sampson SM, et al.: Transcranial magnetic stimulation in the acute treatment of major depressive disorder: clinical response in an open-label extension trial. J Clin Psychiatry. 2008, 69:441-51. 10.4088/jcp.v69n0315

66. Dunner DL, Aaronson ST, Sackeim HA, et al.: A multisite, naturalistic, observational study of transcranial magnetic stimulation for patients with pharmacoresistant major depressive disorder: durability of benefit over a 1-year follow-up period. J Clin Psychiatry. 2014, 75:1394-401. 10.4088/JCP.13m08977

67. Janicak PG, Nahas Z, Lisanby SH, et al.: Durability of clinical benefit with transcranial magnetic stimulation (TMS) in the treatment of pharmacoresistant major depression: assessment of relapse during a 6-month, multisite, open-label study. Brain Stimul. 2010, 3:187-99. 10.1016/j.brs.2010.07.003

68. Gaynes BN, Rush AJ, Trivedi MH, Wisniewski SR, Spencer D, Fava M: The STAR*D study: treating depression in the real world. Cleve Clin J Med. 2008, 75:57-66. 10.3949/ccjm.75.1.57

69. Sackeim HA, Aaronson ST, Carpenter LL, et al.: Clinical outcomes in a large registry of patients with major depressive disorder treated with transcranial magnetic stimulation. J Affect Disord. 2020, 277:65-74. 10.1016/j.jad.2020.08.005

70. Murrough JW, Perez AM, Pillemer S, et al.: Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biol Psychiatry. 2013, 74:250-6. 10.1016/j.biopsych.2012.06.022

71. Rizvi S, Khan AM: Use of transcranial magnetic stimulation for depression. Cureus. 2019, 11:e4736. 10.7759/cureus.4736

72. Jain V, Rath GP, Dash HH, Bithal PK, Chouhan RS, Suri A: Stellate ganglion block for treatment of cerebral vasospasm in patients with aneurysmal subarachnoid hemorrhage - a preliminary study. J Anaesthesiol Clin Pharmacol. 2011, 27:516-21. 10.4103/0970-9185.86598

73. Peterson RC, Patel L, Cubert K, Gulati A: Serial stellate ganglion blocks for intractable postherpetic itching in a pediatric patient: a case report. Pain Physician. 2009, 12:629-32.

74. Parris WC, Reddy BC, White HW, McGrath DM: Stellate ganglion blocks in pediatric patients. Anesth Analg. 1991, 72:552-6. 10.1213/00000539-199104000-00024

75. Dwyer JB, Landeros-Weisenberger A, Johnson JA, et al.: Efficacy of intravenous ketamine in adolescent treatment-resistant depression: a randomized midazolam-controlled trial. Am J Psychiatry. 2021, 178:352-62. 10.1176/appi.ajp.2020.20010018

76. Cullen KR, Amatya P, Roback MG, et al.: Intravenous ketamine for adolescents with treatment-resistant depression: an open-label study. J Child Adolesc Psychopharmacol. 2018, 28:437-44. 10.1089/cap.2018.0030

77. Bejenaru AM, Malhi NK: Use of repetitive transcranial magnetic stimulation in child psychiatry. Innov Clin Neurosci. 2022, 19:11-22.

78. Malone LA, Sun LR: Transcranial magnetic stimulation for the treatment of pediatric neurological disorders. Curr Treat Options Neurol. 2019, 21:58. 10.1007/s11940-019-0600-3

2023 Kuo et al. Cureus 15(8): e43533. DOI 10.7759/cureus.43533

10 of 10